Rare diseases
Investigational molecules
Locations
Back to Italy22 clinical trials in Cefalu', Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis
ItalyStudy on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis
ItalyStudy on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer's Disease
ItalyStudy of LY3541860 and Meglumine Gadoterate for Adults with Relapsing Multiple Sclerosis
ItalyStudy of ACP-204 for Treating Psychosis in Adults with Alzheimer's Disease
ItalyStudy on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis
ItalyStudy of Lecanemab (BAN2401) Treatment in People with Early Alzheimer's Disease: Testing Safety and Effectiveness Over 18 Months
ItalyStudy on the Safety and Efficacy of BIIB091 and Diroximel Fumarate for Patients with Relapsing Multiple Sclerosis
ItalyStudy on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia
ItalyItalyThe busiest research cities in the country
What the registry says about research in the country
Comprehensive studies focusing on various forms of Multiple Sclerosis (MS), including relapsing-remitting and primary progressive types. Research aims to evaluate new therapeutic approaches and long-term treatment effectiveness.
Multiple ongoing trials examining innovative treatments like ABP 692, ocrelizumab, and LY3541860.
Groundbreaking research investigating treatments for Early Alzheimer's Disease and mild cognitive impairment. Studies focus on evaluating new compounds and their effects on disease progression.
Clinical trials examining promising compounds like BAN2401 and GSK4527226 for early intervention.
Diverse studies examining various neurological conditions, including Myasthenia Gravis and MOG antibody-associated disease. Research focuses on innovative treatment approaches.
Investigations include rozanolixizumab for MOGAD and telitacicept for generalized Myasthenia Gravis.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
